PMID- 33489434
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2155-6660 (Print)
IS  - 2155-6660 (Electronic)
IS  - 2155-6660 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Dec 24
TI  - Exploring the burden of short-term CHOP chemotherapy adverse events in 
      post-transplant lymphoproliferative disease: a comprehensive literature review in 
      lymphoma patients.
PG  - 18-26
LID - 10.1080/21556660.2020.1854561 [doi]
AB  - PURPOSE: Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is a 
      treatment for post-transplant lymphoproliferative disease (PTLD) following solid 
      organ transplant (SOT) after failing rituximab, an aggressive and potentially 
      fatal lymphoma. This study explores the humanistic and economic burden of 
      CHOP-associated adverse events (AEs) in PTLD patients. Since PTLD is rare, 
      searches included lymphoproliferative disease with lymphoma patients. DESIGN: 
      This comprehensive literature review used the Preferred Reporting Items for 
      Systematic Review and Meta-Analyses (PRISMA) protocol, pre-specifying the search 
      strategy and criteria. CHOP-associated short-term AEs with an incidence of >4% 
      were sourced from published literature and cancer websites to inform the search 
      strategy. PubMed and EMBASE searches were used to identify humanistic and 
      economic burden studies. RESULTS: PubMed and EMBASE searches identified 3946 
      citations with 27 lymphoma studies included. Studies were methodologically 
      heterogeneous. Febrile neutropenia (FN) was the AE most encountered, followed by 
      chemotherapy-induced (CI) anemia (A), infection, CI-nausea and vomiting, 
      thrombocytopenia, and CI-peripheral neuropathy (PN). FN and infections were 
      associated with significant disutility, increased hospitalization, and extended 
      length of stay (LOS). Infections and CIPN significantly impacted the utility of 
      patients and CIA-related fatigue showed reductions in quality of life (QoL). Many 
      patients continue to have QoL deficits continued even after AEs were treated. 
      Management costs varied greatly, ranging from nominal (CIPN) to over $100,000 in 
      the USA for infections, EUR 10,290 in Europe for infections, or CAN$1012 in 
      Canada for FN. Cost of outpatient care varied but had a lower economic impact 
      compared to hospitalizations. CONCLUSIONS: Short-term AEs from CHOP in the 
      lymphoma population were associated with substantial humanistic and economic 
      burden.
CI  - (c) 2020 Atara Biotherapeutics. Published by Informa UK Limited, trading as Taylor 
      & Francis Group.
FAU - Watson, Crystal
AU  - Watson C
AUID- ORCID: 0000-0001-8763-9197
AD  - Atara Biotherapeutics, Inc, South San Francisco, CA, USA.
FAU - Barlev, Arie
AU  - Barlev A
AD  - Atara Biotherapeutics, Inc, South San Francisco, CA, USA.
FAU - Worrall, Jodie
AU  - Worrall J
AD  - Maple Health Group, New York, NY, USA.
FAU - Duff, Steve
AU  - Duff S
AD  - Veritas Health Economics Consulting, Carlsbad, CA, USA.
FAU - Beckerman, Rachel
AU  - Beckerman R
AD  - Maple Health Group, New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20201224
PL  - England
TA  - J Drug Assess
JT  - Journal of drug assessment
JID - 101672979
PMC - PMC7782278
OTO - NOTNLM
OT  - CHOP
OT  - Stem cell transplant
OT  - adverse events
OT  - cost
OT  - lymphoproliferative disease
OT  - resource use
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
PMCR- 2020/12/24
CRDT- 2021/01/25 05:42
PHST- 2021/01/25 05:42 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
PHST- 2020/12/24 00:00 [pmc-release]
AID - 1854561 [pii]
AID - 10.1080/21556660.2020.1854561 [doi]
PST - epublish
SO  - J Drug Assess. 2020 Dec 24;10(1):18-26. doi: 10.1080/21556660.2020.1854561.